Divi’s Laboratories Q4FY23 net profits down -64% yoy at Rs321 crore on lower sales and supply chain constraints
Divi’s Laboratories reported -22.54% lower sales revenues for the March 2023 quarter on consolidated basis at Rs1,951. Revenues were up 14.24% sequentially. The sharp fall in the sales revenues is most likely attributed to the near zero sales of the anti-COVID treatment drug manufactured by Divi’s Laboratories (Molnupiravir). It also saw pressure on pricing in its core business of APIs (active pharma ingredients) and nutraceuticals.
The sharp fall in operating profits by -61% was largely on account of a double whammy. The costs could not be absorbed properly due to sharply lower sales revenues in the quarter. At the same time, the company also saw pressure on profits from higher raw material costs created by supply chain constraints continuing in many cases. Even for the full year FY23, the total revenues at Rs8,112 crore were lower than Rs9,074 crore in FY22.
Financial highlights for Mar-23 compared yoy and sequentially
| Divi's Laboratories | |||||
Rs in Crore | Mar-23 | Mar-22 | YOY | Dec-22 | QOQ |
| Total Income (Rs cr) | ₹ 1,951 | ₹ 2,518 | -22.54% | ₹ 1,708 | 14.24% |
| Operating Profit (Rs cr) | ₹ 401 | ₹ 1,023 | -60.86% | ₹ 322 | 24.59% |
| Net Profit (Rs cr) | ₹ 321 | ₹ 895 | -64.12% | ₹ 307 | 4.62% |
|
|
|
|
| |
| Diluted EPS (Rs) | ₹ 12.09 | ₹ 33.70 |
| ₹ 11.56 |
|
| OPM | 20.53% | 40.64% |
| 18.83% |
|
| Net Margins | 16.45% | 35.52% |
| 17.97% |
|
For the fourth quarter, Divi’s Laboratories saw operating margins contract from 40.64% to 20.53% yoy while the net profit margins also contracted from 35.52% to 16.45% yoy. The company has declared dividend of Rs30 per share on face value of Rs2 per share, translating into dividend of 1,500%. Net cash from operations were higher on working capital tweaks.
